Aprotinin and lysine analogues in high-risk cardiac surgery [4]

New England Journal of Medicine

Volumn 359, Issue 11, 2008, Pages 1181-1182

  Porte, Robert J ^a   Mallette, Susan V ^b   Burroughs, Andrew K ^b  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFIBRINOLYTIC AGENT; APROTININ; LYSINE; DRUG DERIVATIVE;

BLOOD CONSERVATION; CARDIOVASCULAR RISK; HEART SURGERY; HIGH RISK PATIENT; HUMAN; KIDNEY FAILURE; LETTER; LIVER TRANSPLANTATION; MORTALITY; PRIORITY JOURNAL; STROKE; SURGICAL PATIENT; METHODOLOGY; NOTE; POSTOPERATIVE HEMORRHAGE; BLEEDING;

ANTIFIBRINOLYTIC AGENTS; APROTININ; CARDIAC SURGICAL PROCEDURES; HUMANS; LYSINE; POSTOPERATIVE HEMORRHAGE; RESEARCH DESIGN; BLOOD LOSS, SURGICAL; LIVER TRANSPLANTATION;

EID: 51649125757     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc081370     Document Type: Letter

References (5)

1. Fergusson DA, Hébert PC, Mazer CD, et al. A comparison of aprotinin and lysine analogues in high-risk cardiac surgery. N Engl J Med 2008;358:2319-31.
2. Mangano DT, Tudor IC, Dietzel C. The risk associated with aprotinin in cardiac surgery. N Engl J Med 2006;354:353-65.
3. Ray WA, Stein CM. The aprotinin story - is BART the final chapter? N Engl J Med 2008;358:2398-400.
4. Molenaar IQ, Warnaar N, Groen H, Tenvergert EM, Slooff MJ, Porte RJ. Efficacy and safety of antifibrinolytic drugs in liver transplantation; a systematic review and meta-analysis. Am J Transplant 2007;7:185-94.
5. Warnaar N, Mallett SV, de Boer MT, et al. The impact of aprotinin on renal function after liver transplantation: an analysis of 1,043 patients. Am J Transplant 2007;7:2378-87.